Data from Phase 3 Trial demonstrated improvement in time to relapse, the primary efficacy endpoint, for patients receiving once-monthly aripiprazole IM depot formulation compared to placebo Results ...

PRINCETON, N.J. & DEERFIELD, Ill.--(BUSINESS WIRE)--Otsuka Pharmaceutical Co., Ltd (Otsuka) and H. Lundbeck A/S (Lundbeck) published results from research demonstrating that an investigational ...

Aripiprazole 720mg/2.4mL, 960mg/3.2mL; ext-rel susp for IM inj. Treatment-naive: establish tolerability with oral form first. Give by IM inj into the gluteal muscle. 960mg once every 2 months (56 days ...

(SAN DIEGO, MAY 23, 2007) – In a six-week study in adolescents (13-17 years old) with schizophrenia, the Otsuka Pharmaceutical Co., Ltd. and Bristol-Myers Squibb Company (NYSE: BMY) atypical ...

Oct. 13, 2004 (Stockholm) — The atypical antipsychotic aripiprazole (Abilify) is as effective as haloperidol and significantly more effective than placebo at treating acute agitation in psychotic ...

Pediatr Health. 2010;4(4):375-381. In the retrospective study performed by Valicenti-McDermott and Demb, the mean BMI increased from 23.3 to 24. [17] The change was clinically significant for those ...

The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot. The Food and Drug Administration (FDA) ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Long-acting injectable formulations of paliperidone, ...

NEW YORK CITY -- An investigational 1-day aripiprazole initiation regimen was comparable in efficacy to usual treatment, according to a phase I study presented here. For the treatment of schizophrenia ...